Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LP

Brandes Investment Partners LP decreased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,039,585 shares of the company’s stock after selling 192,019 shares during the period. Brandes Investment Partners LP owned about 0.10% of Takeda Pharmaceutical worth $40,244,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of TAK. FMR LLC lifted its position in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares during the last quarter. Stifel Financial Corp lifted its holdings in Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after acquiring an additional 224,594 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock worth $2,787,000 after acquiring an additional 155,795 shares during the last quarter. Raymond James Financial Inc. bought a new position in Takeda Pharmaceutical in the fourth quarter worth about $1,447,000. Finally, Verition Fund Management LLC bought a new position in Takeda Pharmaceutical in the third quarter worth about $1,533,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $15.02 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average price is $13.76 and its two-hundred day moving average price is $13.92. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.22. The stock has a market capitalization of $47.78 billion, a P/E ratio of 37.54, a P/E/G ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.